Based on the key indicators related to Nurix Therapeutics' liquidity, profitability, solvency, and operating efficiency, Nurix Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Nurix Therapeutics' Other Current Liabilities is fairly stable compared to the past year. Other Liabilities is likely to rise to about 42.9 M in 2024, whereas Total Assets are likely to drop slightly above 318.1 M in 2024. Key indicators impacting Nurix Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Nurix Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Nurix Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Nurix Therapeutics.
Net Income
(136.03 Million)
Nurix
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Long Term Investments
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Non Current Liabilities Other
Net Working Capital
Short Term Debt
Common Stock
Property Plant Equipment
Net Receivables
Retained Earnings Total Equity
Capital Lease Obligations
Short Long Term Debt Total
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Cost Of Revenue
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Nurix Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Nurix Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Nurix Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Nurix Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nurix Therapeutics. Check Nurix Therapeutics' Beneish M Score to see the likelihood of Nurix Therapeutics' management manipulating its earnings.
Nurix Therapeutics Stock Summary
Nurix Therapeutics competes with Foghorn Therapeutics, Shattuck Labs, Monte Rosa, Kymera Therapeutics, and C4 Therapeutics. Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company was incorporated in 2009 and is headquartered in San Francisco, California. Nurix Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Cash flow analysis captures how much money flows into and out of Nurix Therapeutics. It measures of how well Nurix is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Nurix Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Nurix had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Nurix Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Nurix Therapeutics's current stock value. Our valuation model uses many indicators to compare Nurix Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nurix Therapeutics competition to find correlations between indicators driving Nurix Therapeutics's intrinsic value. More Info.
Nurix Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Nurix Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nurix Therapeutics' earnings, one of the primary drivers of an investment's value.
Nurix Therapeutics Systematic Risk
Nurix Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nurix Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Nurix Therapeutics correlated with the market. If Beta is less than 0 Nurix Therapeutics generally moves in the opposite direction as compared to the market. If Nurix Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nurix Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nurix Therapeutics is generally in the same direction as the market. If Beta > 1 Nurix Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Nurix Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nurix Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Nurix Therapeutics growth as a starting point in their analysis.
Nurix Therapeutics November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nurix Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nurix Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nurix Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Nurix Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nurix Therapeutics's daily price indicators and compare them against related drivers.
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.